OncLive TV

Supriya Gupta, MD, discusses updated efficacy data on liso-cel as second-line therapy for large B-cell lymphoma.

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, details the rationale for assessing a dual bispecific CAR T-cell therapy in relapsed/refractory LBCL.

Jue Wang, MD, discusses the challenge of treatment discontinuation in older patients with metastatic castration-resistant prostate cancer.

R. Lor Randall, MD, FACS, discusses the complexity of perivascular epithelioid cell tumors and the critical importance of multidisciplinary care.

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.

Mats Jerkeman, MD, discusses the importance of conducting further research to classify the biological heterogeneity within MCL.

Naseema Gangat, MBBS, discusses the potential use of ruxolitinib and ropeginterferon alfa-2b-njft to reduce JAK2 allele burden in polycythemia vera.

Joseph Vento, MD, discusses the importance of refining RCC classification standards to improve the field’s understanding of the disease’s heterogeneity.

Prerna Mewawalla, MD, discusses needs that remain to be addressed in patients with relapsed/refractory myeloma who receive earlier-line CAR T-cell therapy.

Jyoti Mayadev, MD, discusses the clinical significance of tumor area positivityas a predictive biomarker in locally advanced cervical cancer.

Rocío García-Carbonero, MD, discusses fruquintinib for the treatment of patients with metastatic colorectal cancer.

Shahzad Raza, MD, discusses talquetamab in plus teclistamab in relapsed/refractory multiple myeloma with extramedullary disease.

Naveen Pemmaraju, MD, discusses phase 2 data with pivekimab sunirine in frontline or relapsed/refractory blastic plasmacytoid dendritic cell neoplasms.

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL

Johannes Schetelig, MD, discusses challenges with assessing haploidentical related vs mismatched unrelated donor transplantation in high-risk AML/ALL/MDS

Andrea Visentin, MD, discusses data from an Italian cost analysis of treatment sequencing in CLL.

Balazs Halmos, MD, discusses treatment sequencing considerations in the second line and beyond in NSCLC.

Zeynep Eroglu, MD, discusses management strategies for safe and effective use of encorafenib, binimetinib,and nivolumab in BRAF V600–mutant melanoma.

Neeta Somaiah, MD, discusses the landscape of mutation-specific therapy for the treatment of patients with a gastrointestinal stromal tumor.

Dana E. Rathkopf, MD, discusses the clinical significance of findings from the phase 3 AMPLITUDE trial in HRR gene–mutated mCSPC.

Mats Jerkeman, MD, discusses the use of induction chemoimmunotherapy followed by high-dose chemotherapy and ASCT in younger patients with MCL.

Gerhardt Attard, MD, PhD, FRCP, discusses niraparib plus abiraterone acetate and prednisone in mCSPC with HRR gene alterations.

Jens Bedke, MD, discusses the safety of enfortumab vedotin and pembrolizumab in previously untreated locally advanced or metastatic urothelial carcinoma.

Ajay K. Gopal, MD, FACP, discusses the significance of the FDA approval of tafasitamab for patients with relapsed/refractory follicular lymphoma.

Katherine C. Ansley, MD, highlights the role of elacestrant in treating ER-positive, HER2-negative, ESR1-mutant, advanced breast cancer with metastases.

Zeynep Eroglu, MD, discusses the rationale for evaluating encorafenib plus binimetinib and nivolumab in BRAF V600-mutant melanoma with brain metastases.

R. Lor Randall, MD, FACS, discusses how suboptimal access to multidisciplinary, coordinated care remains a critical barrier to optimal outcomes in sarcoma.

Jessica Paulus, ScD, discusses the clinical implications of using real-world data to add an external control arm to a phase 2 study in HER2+ breast cancer.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.